Product:
Flector Patch
Company:
Alpharma
Continue Reading
Pharmacologic class:
Topical analgesic (nonsteroidal anti-inflammatory drug [NSAID])
Active ingredient:
Diclofenac epolamine 180 mg; per patch.
Indication:
Topical treatment of acute pain due to minor strains, sprains, and contusions.
Pharmacology:
Flector is a topical patch that contains 1.3% of diclofenac epolamine, an NSAID. It measures approximately 10 x14 cm. When applied to intact skin, it provides local analgesia as the drug is released into the skin. Although the exact mechanism by which NSAIDs alleviate pain has not been established, their ability to inhibit the activity of various prostaglandins may play a role.
Following application of a patch to the upper inner arm, peak plasma levels of diclofenac were noted 10-20 hours later. Diclofenac is highly protein-bound; it is eliminated by both renal and hepatic mechanisms.
Clinical trials:
The efficacy of Flector Patch in alleviating acute pain was demonstrated in two studies in patients with minor sprains, strains, and contusions. Patients were randomly assigned to receive either the Flector Patch or a patch that did not contain the active ingredient. In the first study, patients with ankle sprains were treated once daily for one week. In the second study, patients with sprains, strains, and contusions were treated twice daily for up to two weeks. Patients treated with the Flector Patch were found to have experienced a greater reduction in pain as compared with those randomized to placebo patch.
Adults:
Use lowest effective dose for shortest possible duration. Apply one patch to clean, dry, intact skin on most painful area twice daily. May tape edges down if patch begins to peel off. Wash hands after application. Remove during bathing/showering.
Children:
Not recommended.
Contraindications:
Aspirin triad/allergy. Perioperative pain for coronary artery bypass graft. Non-intact or damaged skin (e.g., dermatitis, eczema, burns, wounds).
Precautions:
Advanced renal disease: not recommended. History of ulcer disease or GI bleed, or risks thereof (e.g., concomitant corticosteroids, anticoagulants, smoking, alcohol use, prolonged NSAID therapy). Cardiovascular disease or risk. Hypertension. Heart failure. Fluid retention. Impaired renal or liver function. Monitor BP and for thrombotic and GI events. Not a substitute for corticosteroids. Avoid eyes, mucosa. Handle and dispose of properly. Elderly (monitor renal function). Debilitated. Pregnancy (Cat. C; avoid in late pregnancy). Labor & delivery. Nursing mothers: not recommended.
Interactions:
Avoid concomitant aspirin. May potentiate lithium, methotrexate, warfarin. May antagonize antihypertensive (e.g., ACE inhibitors). Concomitant diuretics, ACE inhibitors: increased risk of renal decompensation.
Adverse reactions:
Skin reactions (e.g., burning, dermatitis, pruritus), GI events (e.g., nausea, dysgeusia, dyspepsia), headache, paresthesia, somnolence. Discontinue if rash or hepatic reaction occurs. See literature re: risk of cardiovascular events, Stevens-Johnson syndrome, toxic epidermal necrolysis, GI ulcer/bleed.
How supplied:
Patch—30
For more information, call 888.840.8884 or visit www.Flectorpatch.com
